Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q1 FY24 Earnings Presentation
30 slides from Dr. Lal Pathlabs's earnings presentation, Jul 27, 2023
Slide 1: Exchange filing cover letter
July 27, 2023 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Symbol: LALPATHLAB Scrip Code: 539524 Sub: Earnings Pr
Slide 2: Dr. Lal PathLabs Limited Q1 FY24 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q1 FY24 Results Presentation July 27, 2023
Slide 3: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr Lal PathLabs Limited (the “Company”) for use in presentati
Slide 4: Table of Contents
Table of Contents Dr Lal PathLabs – At a Glance 4 Overview of Dr Lal PathLabs 5 Key Performance Highlights 6 Financials 7 Operating Highlights 9 Management Commentary 10 Corporate Overview 11 Shareholding 27 Contact Us 28 DISCLAIMER: This presentation may contain ‘forward-looking’ statements at plac
Slide 5: Dr Lal PathLabs – At a Glance
Dr Lal PathLabs – At a Glance India’s Leading 70+ years of 15% 13% 120% & Trusted experience in 3 Year Revenue 3-Year Equity Dividend Diagnostics the field of CAGR Normalised for FY 22-23 Company diagnostics EBITDA CAGR Largest* diagnostics chain in the country 24% 277 5,102 with PAN India presence
Slide 6: Overview of Dr Lal PathLabs
Overview of Dr Lal PathLabs Established Established consumer healthcare brand in diagnostic services brand Pan-India 277 clinical labs (including National Reference Lab at Delhi and Well-positioned integrated Regional Reference labs at Kolkata, Bangalore & Mumbai), 5,102 in one of the coverage Patie
Slide 7: Q1 FY24 – Key Performance Highlights
Q1 FY24 – Key Performance Highlights INR 528 Cr +9.7% Non-Covid Revenue INR 154 Cr 28.4% INR 541 Cr +7.6% Normalised EBITDA* Margin Total Revenue INR 84 Cr 15.4% INR 112 Cr 22% PAT Margin Swasthfit Revenue Contr. * Normalised EBITDA excl. RSU and CSR cost 6
Slide 8: Financials
Financials Particulars (Rs. Cr.) Q1 FY24 Q1 FY23 Gr % FY'23 Revenue 541 503 7.6% 2,017 Operating Expenditure 387 377 1,489 Normalised EBITDA 154 125 22.7% 528 Normalised Margins 28.4% 25.0% 26.2% RSU & CSR cost 8 8 38 EBITDA 146 118 24.4% 490 Margins 27.0% 23.4% 24.3% Other Income 14 8 42 Depreciati
Slide 9: Financial Highlights – Consolidated
Financial Highlights – Consolidated All figures in Rs. Crore Revenue Normalised EBITDA* PBT PAT Non Covid Covid 8% 541 154 503 13 21 125 117 10% 81 Margin 84 482 528 12% Margin Margin Margin Margin 58 Margin 25% 28% 16% 22% 15% Q1 FY23 Q1 FY24 Q1 FY23 Q1 FY24 Q1 FY23 Q1 FY24 Q1 FY23 Q1 FY24 * Normal
Slide 10: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs +61 +2,007 +3,943 277 277 4,731 5,102 9,247 10,599 10,938 216 231 3,705 3,095 6,995 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 No. of Patients (Mn) No. of Samples (Mn) +39% +52% 27.3 26.9 66.0 72.3 19.4 20.3 4
Slide 11: Management Commentary
Management Commentary Commenting on the performance, (Hony) Brig. Dr. Commenting on the performance, Dr. Om Manchanda, Commenting on the performance, Mr. Bharath Arvind Lal, Executive Chairman said: Managing Director said: Uppiliappan, Chief Executive Officer said: “As a frontrunner in organized dia
Slide 12: Corporate Overview
WIDENING y HORIZONS Ox Lat Pathlals ’ ° SERVING Corporate Overview
Slide 13: Vision, Mission & Values
Vision, Mission & Values Be the most trusted Customer First healthcare partner, enabling healthier VISION lives Ethics & Integrity To be an undisputed market Quality leader by providing accessible, VALUES affordable, timely and quality healthcare, diagnostics, applying MISSION Accountability insight
Slide 14: Vibrant Outlook
Vibrant Outlook Evaluate best fit inorganic Strongly develop Rest of India opportunities in South, and leverage geographies, through Regional expertise of recently acquired Reference Labs and cluster city Suburban brand in West approach for attractive markets Target to grow ahead of the industry Dee
Slide 15: DLPL Strategy for future growth
DLPL Strategy for future growth Significantly leverage the Enhance high-end test portfolio of strong digital infrastructure super-specialty & bundled test • Deployed AI, data analytics, machine learning • Created specialty verticals like Genevolve to focus on tools to elevate the patient experience
Slide 16: Leveraging digital infrastructure to make life easier for patient
Leveraging digital infrastructure to make life easier for patient New Website Launch Wallet • New age user intuitive website. • Senior Citizen Wallet: Wallet points on every • Responsive , mobile friendly web designs. booking for Senior Citizen Patients. • SEO friendly for improved customer reach •
Slide 17: Summary highlights – Technical Lab Operations
Summary highlights – Technical Lab Operations LACE and the centre Only lab in India to introduce the First lab to introduce the of excellence in Relaunched the Lipid Donor derived cell free DNA ONCOPRO TSO500 Reproductive panels incorporating the (LIQUID BIOPSY) technique for Comprehensive Genomic m
Slide 18: Savings of >1.3 million aliquots and >5210 tons of plastic waste
Savings of >1.3 million aliquots and >5210 tons of plastic waste in our lab – a strong commitment to sustainability Dr. Lal Pathlabs’ leadership vision focuses on continuous We reduced the need for aliquots by 93% by replacing our previous system configuration1,2 with new, improvement while maintain
Slide 19: Key ESG Initiatives
Key ESG Initiatives Use of Solar E-billing and e- Use of Electric Panels for Power; payment receipt bikes for sample addition of 50 KW to reduce paper collection solar plant at NRL usage Data centre Water saving virtualization to through treatment prevent heat and & reuse of CO2 emission wastewater
Slide 20: Cyber Security Capability
Cyber Security Capability Data Loss • State-of-the-art data loss prevention technology to monitor and prevent the disclosure of information Prevention • Data classification platform for information labeling and handling according to severity of data • Rights management system to enable persistent da
Slide 21: Genevolve: Genetic Testing Division
Genevolve: Genetic Testing Division Onco Genomics Successful completion of 3 years of Launch Wide Test offering with 160+ New Tests Neuro Genomics Wellness Genomics & Pharmacogenomics are upcoming segment Direct reach of 3000+ Doctors Reproductive Genomics Dedicated Business Development team for Gen
Slide 22: Highest Quality Standards in the Industry
Highest Quality Standards in the Industry Best in the Industry CAP Proficiency Testing Score at 99.5% for National Reference Lab Consistently high EQAS Performance Testing Score at 98.5% for Satellite Labs CAP accreditation 2 labs, NABL accreditation 36 Labs 100+ Quality Digitally enabled Real time
Slide 23: Quality Control
Quality Control Laboratory excellence Capability building Test Recommendation engine NABL 133 implementation D L Shah Gold Award for LPL Project ‘Improving Laboratory Performance by developing an in-house automated process to Risk Based Internal Audits monitor Quality control’ PROJECT NEEV- self lea
Slide 24: Enhanced Customer Experience in Home Collection
Enhanced Customer Experience in Home Collection Real time 30 minutes slot visibility & booking D2C- Automated lead management for the patient Digital ID card & ratings of Phlebo Auto Routing engine to dynamically to the patient allocate the booking to nearest available phlebotomist Variable model wh
Slide 25: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Bharath Uppiliappan Ved Prakash Goel Executive Chairman Managing Director Whole-time Director Chief Executive Officer Group Chief Financial Officer Shankha Banerjee Munender Soperna Jai Prakash Meena Manoj Garg
Slide 26: Key Awards & Recognition
Key Awards & Recognition Top 100 Global Most Loved Gold Award Best Brands GAPIO Excellence in Workplace Business Standard Star QCI – D. L. Shah Quality Awards - SME of the year 2022 Healthcare 2022 Diagnostics Award 2023 2022 2022 Diagnostic Chain of the Year – West Financial Express CFO of CSR Awar
Slide 27: Key Awards & Recognition
Key Awards & Recognition Data Quest Technology VC Circle Healthcare Computerworld Dr. Om Manchanda honoured and EY Entrepreneur of The Year Award 2015 – Excellence in Summit 2013 – Best Honors Laureate awarded as ‘Healthcare Personality 2019 – Life Sciences & Implementation of Diagnostic Company Pro
Slide 28: Shareholding as of June, 2023
Shareholding as of 30 June, 2023 23.7% FPIS, FDI & NRIs 55.0% Promoter and Promoter 15.4% Group Others 5.9% Mutual Funds* *Mutual Funds includes Alternate Investment Funds as well 27 27
Slide 29: Contact Us
Contact Us About Dr Lal PathLabs Limited (DLPL) Dr Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests an
Slide 30: Thank you
WIDENING “eo °6@ HORIZONS D2 Lat Pathlals “ : SERVING Thank you